+120.6%
VLO vs MRNA
+945.0%
-824.4%
-20.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.8% | +13.1% | -18.9% | -5.6% |
| 7D | -6.0% | +20.6% | -26.6% | -5.7% |
| 30D | -12.9% | +27.1% | -40.0% | -12.5% |
| 3M | +18.3% | +353.4% | -335.0% | +21.5% |
| 6M | +46.4% | +446.3% | -399.8% | +49.3% |
| YTD | +127.7% | +776.2% | -648.4% | +118.8% |
| 1Y | +120.6% | +987.9% | -867.3% | +102.2% |
| All | +120.6% | +945.0% | -824.4% | +102.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling